MX2009011407A - Antagonistas crig. - Google Patents

Antagonistas crig.

Info

Publication number
MX2009011407A
MX2009011407A MX2009011407A MX2009011407A MX2009011407A MX 2009011407 A MX2009011407 A MX 2009011407A MX 2009011407 A MX2009011407 A MX 2009011407A MX 2009011407 A MX2009011407 A MX 2009011407A MX 2009011407 A MX2009011407 A MX 2009011407A
Authority
MX
Mexico
Prior art keywords
crig
antagonists
erythrocytes
parasites
platelets
Prior art date
Application number
MX2009011407A
Other languages
English (en)
Spanish (es)
Inventor
Menno Van Lookeren Campagne
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39645433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009011407(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2009011407A publication Critical patent/MX2009011407A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009011407A 2007-05-01 2008-04-25 Antagonistas crig. MX2009011407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91534007P 2007-05-01 2007-05-01
PCT/US2008/061513 WO2008137338A1 (en) 2007-05-01 2008-04-25 CRIg ANTAGONISTS

Publications (1)

Publication Number Publication Date
MX2009011407A true MX2009011407A (es) 2009-11-05

Family

ID=39645433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011407A MX2009011407A (es) 2007-05-01 2008-04-25 Antagonistas crig.

Country Status (16)

Country Link
US (1) US20090162356A1 (enExample)
EP (1) EP2152749A1 (enExample)
JP (1) JP2010526076A (enExample)
KR (1) KR20100018523A (enExample)
CN (1) CN101675078A (enExample)
AR (1) AR066375A1 (enExample)
AU (1) AU2008247958A1 (enExample)
BR (1) BRPI0810926A2 (enExample)
CA (1) CA2682835A1 (enExample)
CL (1) CL2008001238A1 (enExample)
IL (1) IL201165A0 (enExample)
MX (1) MX2009011407A (enExample)
PE (1) PE20090239A1 (enExample)
RU (1) RU2009144280A (enExample)
WO (1) WO2008137338A1 (enExample)
ZA (1) ZA200906812B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
SG190596A1 (en) 2008-05-06 2013-06-28 Genentech Inc Affinity matured crig variants
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105924515B (zh) * 2016-04-25 2019-06-14 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110944666B (zh) 2017-06-26 2024-12-31 博奥泰克尼公司 杂交瘤克隆、vsig-4的单克隆抗体，以及制备和使用的方法
EP3873929A4 (en) * 2018-09-28 2022-11-23 Eutilex Co., Ltd. ANTI-HUMAN VSIG4 ANTIBODIES AND USES THEREOF
WO2020236626A1 (en) * 2019-05-17 2020-11-26 Herzlinger George A Methods and systems for treating microbial disease
CA3150807A1 (en) * 2019-09-04 2021-03-11 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
WO2022184853A1 (en) 2021-03-03 2022-09-09 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders

Also Published As

Publication number Publication date
AR066375A1 (es) 2009-08-12
PE20090239A1 (es) 2009-03-19
BRPI0810926A2 (pt) 2014-11-04
RU2009144280A (ru) 2011-06-10
KR20100018523A (ko) 2010-02-17
CN101675078A (zh) 2010-03-17
CL2008001238A1 (es) 2008-11-07
AU2008247958A1 (en) 2008-11-13
JP2010526076A (ja) 2010-07-29
IL201165A0 (en) 2010-05-17
CA2682835A1 (en) 2008-11-13
WO2008137338A1 (en) 2008-11-13
ZA200906812B (en) 2010-12-29
EP2152749A1 (en) 2010-02-17
US20090162356A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
MX2009011407A (es) Antagonistas crig.
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
PL2217287T3 (pl) Artykuł do higieny albo pielęgnacji, zawierający część hydroaktywnych polimerów oraz preparat zawierający bakteriofagi albo co najmniej jeden ich składnik
TN2010000213A1 (en) Wise binding antibodies and epitopes
MY152503A (en) 4-phenyl-pyrane-3, 5-diones, 4-phenyl-thiopyrane-3, 5-diones and cyclohexanetriones as novel herbicides
MY155621A (en) Axl antibodies
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
WO2008097439A3 (en) Anti-autoimmune antibodies for treatment of pemphigus
MX2012001156A (es) Moleculas que contienen boro trisustituidas.
MX362454B (es) Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos.
MX2011012599A (es) Compuestos polimericos de agentes inmunomoduladores.
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
TW200800967A (en) Benzimidazole thiophene compounds
MX343930B (es) Nuevas composiciones y metodos para controlar los nematodos plaga.
EA201170483A1 (ru) Твердая фармацевтическая композиция
EA201000258A1 (ru) Новые гербициды
MX2011013351A (es) Materiales de soporte inorgánicos que contienen compuestos de 3 anillos heterocíclicos.
EA201201623A1 (ru) Лечение диабета 2 типа
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie
EA201001148A1 (ru) Гербицидные комбинации, содержащие дифлуфеникан
WO2014039515A3 (en) Antifungal agents and uses thereof
MX2009013500A (es) Herbicidas novedosos.
WO2011147034A8 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration